Hyperphosphatemia, that is, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease. Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus, and rash. Treatment includes phosphate binders and diuretics.
The Hyperphosphatemia in Chronic Kidney Disease Drugs in Development market research report provides comprehensive information on the therapeutics under development for Hyperphosphatemia in Chronic Kidney Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and features dormant and discontinued projects.
What are the targets of Hyperphosphatemia in the chronic kidney disease pipeline drugs market?
The targets of Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Phosphate and Sodium/Hydrogen Exchanger 3.
Hyperphosphatemia in chronic kidney disease pipeline drugs market, by targets
For more target insights, download a free report sample
What are the mechanisms of action of Hyperphosphatemia in the chronic kidney disease pipeline drugs market?
The mechanisms of action of Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Phosphate Binder and Sodium/Hydrogen Exchanger 3 Inhibitor.
Hyperphosphatemia in chronic kidney disease pipeline drugs market, by mechanisms of action
For more mechanisms of action insights, download a free report sample
What are the routes of administration in Hyperphosphatemia in the chronic kidney disease pipeline drugs market?
The route of administration in Hyperphosphatemia in the chronic kidney disease pipeline drugs market is oral.
What are the molecule types of Hyperphosphatemia in the chronic kidney disease pipeline drugs market?
The molecule types of Hyperphosphatemia in the chronic kidney disease pipeline drugs market are small molecule and polymer.
Hyperphosphatemia in chronic kidney disease pipeline drugs market, by molecule types
For more molecule type insights, download a free report sample
Which are the key companies in Hyperphosphatemia in the chronic kidney disease pipeline drugs market?
The key companies in Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Panion & Bf Biotech Inc, Ardelyx Inc, China Nuokang Bio-Pharmaceutical Inc, Citragen Pharmaceuticals Inc, OPKO Health Inc, Shield Therapeutics Plc, Unicycive Therapeutics Inc, Vidasym Inc, and Vifor Pharma Ltd.
Hyperphosphatemia in chronic kidney disease pipeline drugs market, by key companies
To know more about key companies, download a free report sample
Market report scope
| Targets | Phosphate and Sodium/Hydrogen Exchanger 3 |
| Mechanisms of Action | Phosphate Binder and Sodium/Hydrogen Exchanger 3 Inhibitor |
| Routes of Administration | Oral |
| Molecule Types | Small Molecule and Polymer |
| Key Companies | Panion & Bf Biotech Inc, Ardelyx Inc, China Nuokang Bio-Pharmaceutical Inc, Citragen Pharmaceuticals Inc, OPKO Health Inc, Shield Therapeutics Plc, Unicycive Therapeutics Inc, Vidasym Inc, and Vifor Pharma Ltd |
This report provides:
- A snapshot of the global therapeutic landscape of Hyperphosphatemia in chronic kidney disease.
- Reviews of pipeline therapeutics for Hyperphosphatemia in chronic kidney disease by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
- Key players involved in Hyperphosphatemia in chronic kidney disease therapeutics and enlists all their major and minor projects.
- Assessment of Hyperphosphatemia in chronic kidney disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Hyperphosphatemia in chronic kidney disease.
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia in chronic kidney disease.
- Identify potential new clients or partners in the target demographic.
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
- Devise corrective measures for pipeline projects by understanding Hyperphosphatemia in chronic kidney disease pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
The targets of Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Phosphate and Sodium/Hydrogen Exchanger 3.
The mechanisms of action of Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Phosphate Binder and Sodium/Hydrogen Exchanger 3 Inhibitor.
The route of administration in Hyperphosphatemia in the chronic kidney disease pipeline drugs market is oral.
The molecule types in Hyperphosphatemia in the chronic kidney disease pipeline drugs market are small molecule and polymer.
The key companies in Hyperphosphatemia in the chronic kidney disease pipeline drugs market are Panion & Bf Biotech Inc, Ardelyx Inc, China Nuokang Bio-Pharmaceutical Inc, Citragen Pharmaceuticals Inc, OPKO Health Inc, Shield Therapeutics Plc, Unicycive Therapeutics Inc, Vidasym Inc, and Vifor Pharma Ltd.
